Can acupuncture combined with SSRIs improve clinical symptoms and quality of life in patients with depression? Secondary outcomes of a pragmatic randomized controlled trial

•Deprssed patients could benefit from both manual acupuncture (MA) and electroacupuncture (EA) combined SSRIs treatment.•MA plus SSRIs demostrated more effectiveness in improving core symptoms of depression in psychological impairments,•EA plus SSRIs manifested more improvement in physical/psycholog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Complementary therapies in medicine 2019-08, Vol.45, p.295-302
Hauptverfasser: Zhao, Bingcong, Li, Zhigang, Wang, Yuanzheng, Ma, Xuehong, Wang, Xiangqun, Wang, Xueqin, Liang, Yilin, Yang, Xinjing, Sun, Yang, Song, Meng, Guo, Tianwei, Bao, Tuya, Fei, Yutong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Deprssed patients could benefit from both manual acupuncture (MA) and electroacupuncture (EA) combined SSRIs treatment.•MA plus SSRIs demostrated more effectiveness in improving core symptoms of depression in psychological impairments,•EA plus SSRIs manifested more improvement in physical/psychological symptoms such as anxiety and sleep disturbance. To explore the effects of acupuncture (manual acupuncture or electroacupuncture) combined with SSRIs for moderate to severe depression improving major clinical symptoms and life quality of the patients on secondary outcomes. Pragmatic, parallel, randomized controlled trial. 6 hospitals in China. 6 weeks of manual acupuncture (MA)+selective serotonin reuptake inhibitors (SSRIs), electroacupuncture (EA)+SSRIs, and SSRIs alone. The primary outcome was response rate of 17-item Hamilton Depression Scale (HAMD-17) total score at 6th week. The secondary outcomes reported in this analysis were HAMD-17 factor scores at 1st, 2nd, 4th, 6th, 10th week and WHO Quality of Life-BREF (WHOQOL-BREF) scores at 6th week. 477 patients were randomly assigned into MA + SSRIs (n = 161), EA + SSRIs (n = 160), or SSRIs alone (n = 156) groups. For HAMD-17 (at 6th week), the MA + SSRIs group was significantly better than the SSRIs alone group in retardation factor (p = 0.008), while the EA+SSRIs group was significantly better than the SSRIs alone group in anxiety/somatization factor (p
ISSN:0965-2299
1873-6963
DOI:10.1016/j.ctim.2019.03.015